A Phase 1 Study of XMT-1660 in People with Advanced Solid Tumors (Triple-Negative Breast Cancer)

Full Title

STUDY MER-XMT-1660-1 A PHASE 1, FIRST-IN-HUMAN, DOSE ESCALATION AND EXPANSION, MULTICENTER STUDY OF XMT-1660 IN PARTICIPANTS WITH SOLID TUMORS

Purpose

The purpose of this study is to find the highest dose of the investigational drug XMT-1660 that can be given safely in people with advanced triple-negative breast cancer (TNBC) that persists despite prior chemotherapy. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.

TNBC frequently expresses a protein called B7-H4, which contributes to the growth of cancer cells. By blocking this protein, XMT-1660 may help slow or stop TNBC growth. It is given intravenously (by vein) every 3 weeks.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Nour Abuhadra at 646-888-4451.